Review: Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients

Abstract

The treatment of chronic hepatitis C is a rapidly changing arena with new medications, new guidelines, and an evolving understanding of the virus, host factors and natural history. With the explosion of new information, the educational infrastructure to update clinicians has been outpaced; many feel uncertain if the tools they are using to care for patients are meeting the standard of practice. This review focuses on the most common genotype of the hepatitis C virus and the rules of engagement when treating with pegylated interferon and ribavirin. Viral assessment guideposts are evaluated and put into context for a clinical audience. The expected arrival of newer antiviral therapies is still years away, and maximizing the current treatment regimens is of utmost importance to eradicate virus when feasible, while minimizing toxicity.

Keywords

hepatitis C virus pegylated interferon ribavirin positive predictive value negative predictive value rapid virologic response early virologic response relapse

References

Berg, T. , von Wagner, M. , Nasser, S. , Sarrazin, C. , Heintges, T. , Gerlach, T. et al. (2006) Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferonalfa-2a plus ribavirin, Gastroenterology 130: 1086-1097.

Crespo, M. , Sauleda, S. , Esteban, J.I. , Juarez, A. , Ribera, E. , Andreu, A.L. et al. (2007) Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients, Viral Hepat 14: 228-238.

Davis, G.L. , Wong, J.B. , McHutchison, J.G. , Manns, M.P. , Harvey, J. and Albrecht, J. (2003) Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C, Hepatology 38: 645-652.

Fried, M.W. , Shiffman, M.L. , Reddy, K.R. , Smith, C. , Marinos, G. , Gonçales, F.L. Jr et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Engl J Med 347: 975-982.

Hadziyannis, S.J. , Sette Jr, H. , Morgan, T.R. , Balan, V. , Diago, M. , Marcellin, P. et al. (2004) Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose, Ann Intern Med 140: 346-355.

Jensen, D.M. , Morgan, T.R. , Marcellin, P. , Pockros, P.J. , Reddy, K.R. , Hadziyannis, S.J. et al. (2006) Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy, Hepatology 43: 954-960.

Lee, S.S. , Heathcote, E.J. , Reddy, K.R. , Zeuzem, S. , Fried, M.W. , Wright, T.L. et al. (2002) Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD), J Hepatol 37: 500-506.

Mangia, A. , Minerva, N. , Bacca, D. , Cozzolongo, R. , Ricci, G.L. , Carretta, V. et al. (2008) Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial, Hepatology 47: 43-50.

Manns, M.P. , McHutchison, J.G. , Gordon, S.C. , Rustgi, V.K. , Shiffman, M. , Reindollar, R. et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet 358: 958-965.

10.

Marcellin, P. , Jensen, D.M. , Hadziyannis, S.J. and Ferenci, P. (2007) Differentiation of early virologic response (EVR) into RVR, complete EVR (CEVR) and partial EVR (PEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40kd) (Pegasys®) and ribavirin (Copegus®), Hepatology 46: 818A.

11.

Payan, C. , Pivert, A. , Morand, P. , Fafi-Kremer, S. , Carrat, F. , Pol, S. et al. (2007) Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients, Gut 56: 1111-1116.

12.

Pearlman, B.L. , Ehleben, C. and Saifee, S. (2007) Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders, Hepatology 46: 1688-1694.

13.

Poordad, F. , Reddy, K.R. and Martin, P. (2008) Rapid virologic response: a new milestone in the management of chronic hepatitis C, Clin Infect Dis 46: 78-84.

14.

Sanchez-Tapias, J.M. , Diago, M. , Escartin, P. , Enríquez, J. , Romero-Gómez, M. , Bárcena, R. et al. (2006) Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment, Gastroenterology 131: 451-460.

15.

Segadas-Soares, J.A. , Villela-Nogueira, C.A. , Perez, R.M. , Nabuco, L.C. , Brandao-Mello, C.E. and Coelho, H.S.M. (2006) HCV-RNA in the fourth week as a predictive factor of sustained virological response (SVR) in genotype 1 hepatitis C patients treated with peg-interferon-a2b (PEG-IFN-a2b) and ribavirin, Hepatology 44(Suppl. 1): A384.

16.

Sulkowski M. , Lawitz, E. , Shiffman M.L. , Muir A.J. , Galler G. , McCone J. et al. (2008a) Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study [oral presentation]. Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy, 26 April 2008.

17.

Sulkowski, M. , Vierling, J.M. , Brown, K. , Flamm, S. , Kwo, P. and Mullen, K. (2008b) Probability of sustained virologic response (SVR) is associated with the magnitude of HCV RNA reduction at week 4 of treatment with peginterferon (Peg) plus ribavirin (RBV): results of the IDEAL trial , Hepatology 48(Suppl. 4): A1868.

18.

Torriani, F.J. , Rodriguez-Torres, M. , Rockstroh, J.K. , Lissen, E. , Gonzalez-García, J. , Lazzarin, A. et al. (2004) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients, N Engl J Med 351: 438-450.

19.

Yu, M.L. , Dai, C.Y. , Huang, J.F. and Chuang, W.L. (2008) Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial, Hepatology 47: 1884-1893.

20.

Zeuzem, S. , Buti, M. , Ferenci, P. , Sperl, J. , Horsmans, Y. , Cianciara, J. et al. (2006) Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia, J Hepatol 44: 97-103.